Jason M. Broderick

In the ARAMIS trial, darolutamide reduced the risk of death by 31% compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

The goal of the study is to establish real-world efficacy evidence of using the Soltive Laser System for laser lithotripsy.

The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.

The combination of eganelisib and nivolumab demonstrated promising activity and was well tolerated in a phase 2 trial of patients with advanced urothelial cancer.

The FDA approved relugolix in December 2020 for the treatment of patients with advanced prostate cancer.

A new drug application has been filed for SOV2012-F1 (Kyzatrex) for the treatment of adult men with primary or secondary hypogonadism.

The research involved examining circulating markers of inflammation in patients with prostate cancer receiving androgen-deprivation therapy.

Combining telaglenastat with cabozantinib did not improve outcomes versus cabozantinib alone in a phase 2 trial.

The approval was based on the phase 3 EMPOWUR trial.

The researchers recommend patient counseling on these side effects and routine monitoring of cognitive function in patients receiving ADT.

Combining the novel interleukin-15 superagonist complex N-803 (Anktiva) with BCG led to a high complete response rate in patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.

The approval of the GnRH receptor antagonist is based on data from the phase 3 HERO study.

Existing evidence does not clarify which patients with acute ureteral colic would benefit most from early surgical intervention.

The new drug application for 18F-DCFPyL is supported by results from the OSPREY and CONDOR trials.

The PD-L1 inhibitor has been recommended for approval in this setting based on data from the phase 3 JAVELIN Bladder 100 study.

The phase 2 study has a targeted enrollment of 37 patients and a primary end point of complete response.

Over half of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

Researchers examined the prevalence of germline mutations, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.

Clinical activity with MK-6482 was observed in both RCC and non-RCC lesions.

Blue light cystoscopy identified patients with bladder cancer recurrence post-BCG that would have been missed with standard white light cystoscopy alone.

A separate analysis presented at SUO assessed the impact of nadofaragene firadenovec on the incidence and time to cystectomy.

“Further prospective studies are warranted to identify potential mechanisms and to develop strategies that include a fall risk assessment tool to examine the risk factors for falls or fracture,” the authors wrote.

“These data published in the Lancet Oncology show that nadofaragene firadenovec, a first-of-its-kind therapy, may be an effective treatment option for BCG-unresponsive non-muscle invasive bladder cancer patients,” Colin P. N. Dinney, MD.

At a median follow-up of 15 years, the pooled analysis showed statistically significant improvements with adjuvant ADT over neoadjuvant ADT in biochemical failure, distant metastasis, and progression-free survival rates.

The vaccine RV001 targets RhoC, a small GTPase that is overexpressed in advanced solid tumors.

The treatment is approved for both adult and pediatric patients.

An application for the eCoin device has been submitted to the FDA for regulatory approval.

The FDA is considering an application for vibegron for the treatment of patients with OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The new fixed-dose schedule is approved for all of durvalumab's FDA indications, including advanced bladder cancer.

The risk of stricture recurrence was higher with endoscopic surgery compared with urethroplasty.